Literature DB >> 2537584

Biochemistry of Pentostam resistant Leishmania.

J D Berman1, N Edwards, M King, M Grogl.   

Abstract

Promastigotes of Leishmania mexicana amazonensis WR 669 clone 4 were made resistant to antimony in the form of Pentostam (sodium stibogluconate) by exposure to media containing increasing concentrations of Sb. The dose of Sb expected to kill 50% of promastigotes and amastigotes of the parent sensitive clone (WR 669) and the resistant clone (WR 669R) was determined by exposure of suspensions in physiologic salt solution for 3 hr. The approximate Ed50s in microgram Sb/ml were: 10,000 for WR 669R promastigotes; 7,000 for WR 669R amastigotes; 200 for WR 669 promastigotes; and 150 for WR 669 amastigotes. Thus, Sb resistance and Sb sensitivity expressed by promastigote clones are also expressed by their respective amastigotes. Studies with 125Sb-Pentostam showed that WR 669R amastigote resistance was not due to altered Sb uptake over 1 hr. When amastigotes pretreated with Pentostam were incubated with 14C labeled metabolic precursors, susceptibility to Sb was correlated with inhibition of glycolytic enzymes and of fatty acid beta-oxidation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2537584     DOI: 10.4269/ajtmh.1989.40.159

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  14 in total

Review 1.  Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs.

Authors:  O Kayser; C Olbrich; S L Croft; A F Kiderlen
Journal:  Parasitol Res       Date:  2002-12-11       Impact factor: 2.289

2.  Vaccination of humans against cutaneous leishmaniasis: cellular and humoral immune responses.

Authors:  E Nascimento; W Mayrink; C A da Costa; M S Michalick; M N Melo; G C Barros; M Dias; C M Antunes; M S Lima; D C Taboada
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.441

3.  Glibenclamide, a blocker of K+(ATP) channels, shows antileishmanial activity in experimental murine cutaneous leishmaniasis.

Authors:  Xenón Serrano-Martín; Gilberto Payares; Alexis Mendoza-León
Journal:  Antimicrob Agents Chemother       Date:  2006-10-02       Impact factor: 5.191

4.  Pentostam induces resistance to antimony and the preservative chlorocresol in Leishmania donovani promastigotes and axenically grown amastigotes.

Authors:  M Ephros; E Waldman; D Zilberstein
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 5.  Leishmania antimony resistance: what we know what we can learn from the field.

Authors:  Khatima Aït-Oudhia; Elodie Gazanion; Baptiste Vergnes; Bruno Oury; Denis Sereno
Journal:  Parasitol Res       Date:  2011-07-29       Impact factor: 2.289

6.  Oral Therapy with Amlodipine and Lacidipine, 1,4-Dihydropyridine Derivatives Showing Activity against Experimental Visceral Leishmaniasis.

Authors:  Partha Palit; Nahid Ali
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

7.  Resistance of Leishmania (Viannia) braziliensis to nitric oxide: correlation with antimony therapy and TNF-alpha production.

Authors:  Anselmo S Souza; Angela Giudice; Júlia Mb Pereira; Luís H Guimarães; Amelia R de Jesus; Tatiana R de Moura; Mary E Wilson; Edgar M Carvalho; Roque P Almeida
Journal:  BMC Infect Dis       Date:  2010-07-15       Impact factor: 3.090

8.  Suppression of both antimony-susceptible and antimony-resistant Leishmania donovani by a bis(benzyl)polyamine analog.

Authors:  R J Baumann; W L Hanson; P P McCann; A Sjoerdsma; A J Bitonti
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

Review 9.  Practical guide for the treatment of leishmaniasis.

Authors:  R N Davidson
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

10.  The antileishmanial agent licochalcone A interferes with the function of parasite mitochondria.

Authors:  L Zhai; J Blom; M Chen; S B Christensen; A Kharazmi
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.